Evaluation of the effect of modulator therapies on medication complexity in adult cystic fibrosis patients
Pulmonary Pharmacology and Therapeutics, cilt.93, 2026 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 93
- Basım Tarihi: 2026
- Doi Numarası: 10.1016/j.pupt.2026.102420
- Dergi Adı: Pulmonary Pharmacology and Therapeutics
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, Chemical Abstracts Core, EMBASE, MEDLINE, Academic Search Ultimate (EBSCO)
- Anahtar Kelimeler: Complexity, Cystic fibrosis, Medication, Modulators
- Hacettepe Üniversitesi Adresli: Evet
Özet
Background: The positive effects of modulator therapies (MT) on various symptoms have been proven. There is no clear recommendation for stopping or reducing the dose of other therapies after using modulators. However, patients may feel better and stop their other therapies. The aim of this study was to compare Medication Regimen Complexity Index (MRCI) and Treatment Complexity Score (TCS) scores of adult CF patients before and after 1 year of their MT use and also to compare them with non-MT patients. Methods: The medications and forced expiratory volume in 1 s (FEV1) of patients using MT were recorded on the first day and after 1 year, and those non-MT were recorded at 1-year intervals. MRCI and TCS were recorded simultaneously. Results: In total, 105 patients were included (48.6% MT). Dornase alfa use decreased significantly in the MT group (p < 0.001), while azithromycin use increased significantly in the non-MT group (p = 0.016). No significant change was observed in the use of other therapies. In the MT, mean (SD) MRCI and TCS decreased significantly [28.37 (10.39) vs 23.77 (10.90); p < 0.001 and 8.86 (3.37) vs 7.51 (3.29); p < 0.001]. In the non-MT, mean (SD) MRCI and TCS increased significantly [23.65 (12.86) vs 26.13 (14.68); p < 0.001, and 7.29 (4.21) vs 7.79 (4.61) p = 0.021]. A negative significant correlation was observed between MRCI (p < 0.001), TCS (p < 0.001) and FEV1% at baseline and after 1-year. Conclusion: A decrease in the use of inhaled therapy was observed in MT group after 1 year. Our study demonstrates that patients receiving MT exhibit a reduction in medication use, whereas those not receiving MT show an increase, suggesting that MT may contribute to decreased treatment burden without worsening clinical outcomes in CF management.